BMS-986405

DRUG2 trials

Sponsors

Celgene

Conditions

Multiple Myeloma

Phase 1

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

TerminatedNCT04036461

CelgeneMultiple Myeloma

Start: 2019-08-26End: 2024-08-19Updated: 2024-08-30

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

TerminatedNCT04855136

CelgeneMultiple Myeloma

Start: 2021-06-01End: 2025-04-25Updated: 2025-09-11

Related Papers

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.

2023-08-1791 citations

KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Blood2021-11-059 citations